AHA Conference CoverageNovember 11-15, 2017 | By Christine Welniak
New risk models and strategies for care are needed for cardiac disease in pregnant women in East Africa [Read more]
Does the effectiveness of once-weekly exenatide vary according to a patient’s baseline risk?
A new analysis of the RE-VERSE AD study shows that idarucizumab achieves normal hemostasis in dabigatran-treated patients needing emergency surgery [Read more]
The 2017 guideline includes the first use of value statements as well as recommendations for shared decision making and terminal care [Read more]
Time to reperfusion matters—faster treatment times can reduce mortality [Read more]
An innovative approach reduced the rate of postoperative atrial fibrillation and the duration of the first episode [Read more]
Patients “matched” for donor-specific antibodies did not reach the primary endpoint—but unmatched patients did [Read more]